Summary
This article discusses results of 2 48-week, randomized, double-blind, placebo-controlled clinical trials that evaluated the humanized anti-CD22 monoclonal antibody epratuzumab for the treatment of patients with severe BILAG A or moderate BILAG B (in =2 organ systems) systemic lupus erythematosus flares.
- rheumatology clinical trials
- lupus
- © 2008 MD Conference Express
Tools
Randomized Controlled Trials of Epratuzumab Reveal Clinically Meaningful Improvements in Patients with Moderate/Severe SLE Flares
Permalink:
Table of contents
Cited By...
- No citing articles found.